Cambient Family Office LLC Makes New $737,000 Investment in Amgen Inc. $AMGN

Cambient Family Office LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,253 shares of the medical research company’s stock, valued at approximately $737,000.

Other large investors also recently modified their holdings of the company. Anfield Capital Management LLC lifted its stake in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its holdings in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in Amgen in the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC acquired a new stake in Amgen during the 4th quarter valued at approximately $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 1.2%

NASDAQ:AMGN opened at $337.60 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The business’s 50 day moving average is $340.96 and its two-hundred day moving average is $345.81. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a market cap of $182.21 billion, a PE ratio of 23.49, a P/E/G ratio of 3.43 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the firm earned $4.90 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. The Goldman Sachs Group set a $389.00 price objective on Amgen in a report on Friday, June 5th. Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Leerink Partners restated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Finally, Morgan Stanley increased their price objective on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.